Impact of tumor volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab

Key Points

• This research aims to understand how tumor volume influences progression-free survival in lung cancer patients undergoing treatment.
• Analyzed tumor volume as a prognostic factor for patient outcomes.
• Evaluated progression-free survival as the primary outcome measure.
• Utilized chemoradiotherapy and durvalumab as treatment protocols.
• Tumor volume significantly correlates with progression-free survival.
• Patients with smaller tumor volumes experience better outcomes.
• Findings support the use of tumor volume in treatment planning and risk assessment.